Matrix Metalloproteinase Polymorphisms Are Associated with Bladder Cancer Invasiveness

Purpose: Matrix metalloproteinases (MMP) promote tumor invasion and alter microenvironment. MMP levels are elevated in bladder cancer patients correlating with more advanced stage. We tested whether polymorphisms in MMP genes modify the risk of bladder cancer invasiveness and whether smoke exposure modifies this risk. Experimental Design: Using a case-only study, we examined the association of 11 single-nucleotide polymorphisms and one microsatellite polymorphism in MMP genes MMP1, MMP2, MMP3, MMP8, MMP9, and MMP12 with the risk of invasive bladder cancer in 243 Caucasian patients with muscle invasive compared with 315 Caucasian patients with superficial disease. Results: The MMP9 microsatellite ≥24 CA repeat and MMP12 −82 G alleles were associated with a higher risk of bladder cancer invasiveness [odds ratio (OR), 3.10; 95% confidence interval (95% CI) 1.17-8.23 and OR, 1.50; 95% CI, 1.00-2.28, respectively]. Ever smokers with the MMP9 ≥24 CA repeat allele had a 5.16-fold (95% CI, 1.56-17.1) increased risk of invasiveness compared with wild-type never smokers. Ever smokers with the MMP12 G allele also had an increased risk of bladder cancer invasiveness (OR, 2.32; 95% CI, 1.30-4.12). Conclusions: Our results suggest that genetic changes in MMPs are associated with the development of invasive bladder cancer.

[1]  M. Oka,et al.  Association of functional polymorphisms of matrix metalloproteinase (MMP)‐1 and MMP‐3 genes with colorectal cancer , 2002, International journal of cancer.

[2]  S. Ye.  Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[3]  Xue-Ru Wu.  Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.

[4]  Y. Oh,et al.  Lung matrix metalloproteinase-9 correlates with cigarette smoking and obstruction of airflow. , 2003, Journal of Korean medical science.

[5]  J. Lunec,et al.  Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine , 2003, BJU international.

[6]  Hongbing Shen,et al.  Functional Polymorphisms of Matrix Metalloproteinase-9 Are Associated with Risk of Occurrence and Metastasis of Lung Cancer , 2005, Clinical Cancer Research.

[7]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[8]  R. Zivadinov,et al.  MMP-9 microsatellite polymorphism and multiple sclerosis , 2004, Journal of Neuroimmunology.

[9]  E Dorant,et al.  The impact of characteristics of cigarette smoking on urinary tract cancer risk , 2000, Cancer.

[10]  Sang-Oh Yoon,et al.  Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. , 2003, Journal of biochemistry and molecular biology.

[11]  J. Gu,et al.  Matrix metalloproteinase polymorphisms and bladder cancer risk. , 2006, Cancer research.

[12]  A M Zeiher,et al.  Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. , 2000, Circulation research.

[13]  J. Richie,et al.  Biology and management of bladder cancer. , 1990, The New England journal of medicine.

[14]  R. Khokha,et al.  Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development , 2003, British Journal of Cancer.

[15]  A. Evans,et al.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. , 1999, Circulation.

[16]  B. Baxter,et al.  MMP-9 microsatellite polymorphism: association with the progression of intima-media thickening and constrictive remodeling of carotid atherosclerotic plaques. , 2005, Atherosclerosis.

[17]  H. Sato,et al.  v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. , 1993, The Journal of biological chemistry.

[18]  Y. Sasaguri,et al.  Shortened microsatellite d(CA)21 sequence down‐regulates promoter activity of matrix metalloproteinase 9 gene , 1999, FEBS letters.

[19]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[20]  W. M. Linehan,et al.  Associations between Bladder Cancer Risk Factors and Tumor Stage and Grade at Diagnosis , 1994, Epidemiology.

[21]  M. Parodi,et al.  MMP-9 microsatellite polymorphism and susceptibility to exudative form of age-related macular degeneration , 2005, Genetics in Medicine.

[22]  M. Biondi,et al.  MMP1 and MMP3 polymorphisms in promoter regions and cancer. , 2000, Clinical chemistry.

[23]  J. Kos,et al.  Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  Y. Chu,et al.  Shortening of microsatellite deoxy(CA) repeats involved in GL331-induced down-regulation of matrix metalloproteinase-9 gene expression. , 2003, Biochemical and biophysical research communications.

[25]  B. Aggarwal,et al.  Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. , 2004, Cancer research.

[26]  Huda Y. Zoghbi,et al.  Diseases of Unstable Repeat Expansion: Mechanisms and Common Principles , 2005, Nature Reviews Genetics.

[27]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[28]  M A Moses,et al.  Increased incidence of matrix metalloproteinases in urine of cancer patients. , 1998, Cancer research.

[29]  M. Björklund,et al.  Gelatinase-mediated migration and invasion of cancer cells. , 2005, Biochimica et biophysica acta.

[30]  O. Yoshida,et al.  Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. , 1999, The Journal of urology.

[31]  Y. Nakamura,et al.  Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. , 1999, Cancer research.

[32]  H Yonas,et al.  Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. , 1999, Stroke.

[33]  W. Parks,et al.  Role of Matrix Metalloproteinases in Abdominal Aortic Aneurysms a , 1996, Annals of the New York Academy of Sciences.

[34]  S. Loening,et al.  Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. , 2001, Urology.

[35]  N. Jarjour,et al.  Role of matrix metalloproteinases in asthma , 2003, Current opinion in pulmonary medicine.

[36]  R. Millikan,et al.  Focus on bladder cancer. , 2004, Cancer cell.

[37]  Diana Duplij,et al.  DNA sequence representation by trianders and determinative degree of nucleotides. , 2005, Journal of Zhejiang University. Science. B.

[38]  D. Close,et al.  Matrix metalloproteinase inhibitors in rheumatic diseases , 2001, Annals of the rheumatic diseases.

[39]  S. Ye.  Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. , 2006, Cardiovascular research.

[40]  S. M. Park,et al.  Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. , 2005, The Journal of biological chemistry.

[41]  D. Grignon,et al.  High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. , 1996, Cancer research.

[42]  G. Striker,et al.  Association of a decreased number of d(CA) repeats in the matrix metalloproteinase-9 promoter with glomerulosclerosis susceptibility in mice. , 2002, Journal of the American Society of Nephrology : JASN.

[43]  S. M. Park,et al.  Proteolytic Cleavage of Extracellular Secreted α-Synuclein via Matrix Metalloproteinases* , 2005, Journal of Biological Chemistry.

[44]  L. Nakopoulou,et al.  Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.